Form 8-K · Current report
Vertex Pharmaceuticals 8-K, filed Aug 3, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000256
Summary
Vertex Pharmaceuticals reported second-quarter 2026 total revenue of $3.33 billion, up 12% from a year earlier, and raised its full-year 2026 revenue guidance to $13.1–13.2 billion from $12.95–13.1 billion. Vertex also said it has agreed to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026, and that its povetacicept program has a PDUFA date of November 30.
Key points
- Second-quarter 2026 revenue rose 12% to $3.33 billion, with U.S. revenue up 11% to $2.06 billion and revenue outside the U.S. up 14% to $1.28 billion.
- CASGEVY revenue was $76 million in the quarter and JOURNAVX revenue was $50 million; Vertex said the FDA recently approved CASGEVY for children 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia.
- Vertex reiterated full-year 2026 combined GAAP R&D, AIPR&D and SG&A expense guidance of $6.3–6.45 billion and non-GAAP guidance of $5.65–5.75 billion.
- Cash, cash equivalents, and marketable securities were $13.6 billion as of June 30, 2026, versus $12.3 billion at December 31, 2025.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 3, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.